Trial Profile
An Open-label Phase II Trial of Panitumumab Plus Irinotecan for Patients With Advanced Metastatic Colorectal Cancer Without KRAS Mutation (Wild-type) in Third-line Chemotherapy (FOLFOX/XELOX ± Bevacizumab and Irinotecan Alone or FOLFIRI/CAPIRI ± Bevacizumab)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Biomarker; Therapeutic Use
- Acronyms PIMABI
- 22 Aug 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
- 30 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Apr 2008 New trial record.